Autoimmune hepatitis
Conditions
Interventions
None listed
Sponsors
Maag Darm en Leverziekten
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients are older than 18 years old Patients with AIH (at least probable according to the simplified criteria) or overlapsyndrome Patients are treated for at least 6 months Patients have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Current flair of autoimmune hepatitis (ALT more than 3 times the upper limit of normal) Patients with signs of other liver diseases as NASH, alcoholic liver disease, viral hepatitis, hemochromatosis or Wilson's disease Patients with current decompensated liver disease (recompensated patients can be included)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main endpoint is a multivariate regression of treatment response, fibrosis and immunological markers for predicting increase in fibrosis as measured by liver elastography | — |
Secondary
| Measure | Time frame |
|---|---|
| Amount of fibrosis at inclusion Difference in fibrosis at inclusion and 5 years Correlation between fibrosismarkers, immunological markers and liver stiffness Quality of life | — |
Countries
Netherlands
Outcome results
None listed